The New Paradigm in Early Lyme Borreliosis Detection - Brochure

LIAISON® LymeDetect® is an innovative approach to EARLY Lyme disease diagnostics that combines assays measuring B cell response, LIAISON® IgG and IgM CLIA assays, and T cell response with the patented QuantiFERON® IGRA technology. This new diagnostic solution has demonstrated a significant improvement in sensitivity vs standard two-tiered testing (sTTT) in the first 21 days of the infection, from 48.5% (sTTT) to the 73.5% of LIAISON® LymeDetect®.